Hepatitis C Virus NS3/4A Serine Protease Inhibitors

Hepatitis C virus NS3/4A serine protease inhibitors are a class of direct-acting antiviral medications specifically indicated for the treatment of chronic hepatitis C virus infection Typically administered in oral combination regimens alongside other direct-acting antivirals, they play a central role in achieving high rates of sustained virologic response across multiple viral genotypes

Hepatitis C virus NS3/4A serine protease inhibitors are a class of direct-acting antiviral medications specifically indicated for the treatment of chronic hepatitis C virus infection These agents function by selectively binding to and inhibiting the viral NS3/4A serine protease complex, an enzyme essential for cleaving the translated viral polyprotein into mature, functional nonstructural proteins By blocking this post-translational processing, they prevent viral replication and assembly

These agents function by selectively binding to and inhibiting the viral NS3/4A serine protease complex, an enzyme essential for cleaving the translated viral polyprotein into mature, functional nonstructural proteins

By blocking this post-translational processing, they prevent viral replication and assembly

Typically administered in oral combination regimens alongside other direct-acting antivirals, they play a central role in achieving high rates of sustained virologic response across multiple viral genotypes